Cargando…

Small heterodimer partner as a predictor of neoadjuvant radiochemotherapy response and survival in patients with rectal cancer: A preliminary study

Small heterodimer partner (SHP) plays an essential role in the regulation of innate immune and inflammatory responses. The aim of the present study was to identify whether SHP levels are associated with cancer immunology and treatment outcomes in rectal cancer. SHP expression was analyzed via gene s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sup, Joo, Mina, Yeo, Min-Kyung, Cho, Moon-June, Kim, Jun-Sang, Jo, Eun-Kyeong, Kim, Jin-Man
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358587/ https://www.ncbi.nlm.nih.gov/pubmed/34457063 http://dx.doi.org/10.3892/ol.2021.12969

Ejemplares similares

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications
por: Schiffmann, Leif, et al.
Publicado: (2013)

Small Heterodimer Partner and Innate Immune Regulation
por: Yuk, Jae-Min, et al.
Publicado: (2016)

Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy
por: Rodríguez-Tomàs, Elisabet, et al.
Publicado: (2021)

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer
por: Dröge, Leif Hendrik, et al.
Publicado: (2021)

Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome
por: Yang, Chul-Su, et al.
Publicado: (2015)

Small Heterodimer Partner-Targeting Therapy Inhibits Systemic Inflammatory Responses through Mitochondrial Uncoupling Protein 2
por: Yang, Chul-Su, et al.
Publicado: (2013)

Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors
por: Ferrigno, Robson, et al.
Publicado: (2006)

Anastomotic Breakdown Five Years After Neoadjuvant Radiochemotherapy and Ultralow Anterior Resection for Rectal Adenocarcinoma
por: Nguyen, Eric, et al.
Publicado: (2020)

Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker
por: Kim, Sup, et al.
Publicado: (2022)

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
por: Derbel, Olfa, et al.
Publicado: (2013)

Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis
por: Schiffmann, Leif, et al.
Publicado: (2013)

Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI
por: Bostel, T., et al.
Publicado: (2020)

High-Risk Clinicopathological and Genetic Features and Outcomes in Patients Receiving Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer
por: del Carmen, Sofía, et al.
Publicado: (2021)

Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer
por: Rendl, Gundula, et al.
Publicado: (2014)

Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc(+) Monocytes in Rectal Cancer
por: Wagner, Felix, et al.
Publicado: (2019)

Forecasting Individual Patients’ Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy
por: Martorana, Emanuele, et al.
Publicado: (2023)

Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner
por: Bae, Eun Hui, et al.
Publicado: (2014)

Diffusion-Weighted Magnetic Resonance Application in Response Prediction before, during, and after Neoadjuvant Radiochemotherapy in Primary Rectal Cancer Carcinoma
por: Musio, Daniela, et al.
Publicado: (2013)

Avoiding Unnecessary Major Rectal Cancer Surgery by Implementing Structural Restaging and a Watch-and-Wait Strategy After Neoadjuvant Radiochemotherapy
por: Huisman, J. F., et al.
Publicado: (2020)

Influence of Gender on Radiosensitivity during Radiochemotherapy of Advanced Rectal Cancer
por: Schuster, Barbara, et al.
Publicado: (2021)

Small heterodimer partner (SHP) deficiency protects myocardia from lipid accumulation in high fat diet-fed mice
por: Ohn, Jung Hun, et al.
Publicado: (2017)

Thyroid Hormone Regulates the mRNA Expression of Small Heterodimer Partner through Liver Receptor Homolog-1
por: Ahn, Hwa Young, et al.
Publicado: (2015)

Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy
por: Nicosia, Luca, et al.
Publicado: (2018)

Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer
por: JANKARASHVILI, Natalia, et al.
Publicado: (2019)

G protein coupling and activation of the metabotropic GABA(B) heterodimer
por: Yang, Moon Young, et al.
Publicado: (2022)

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
por: Negri, F V, et al.
Publicado: (2008)

Impact on Loco-regional Control of Radiochemotherapeutic Sequence and Time to Initiation of Adjuvant Treatment in Stage II/III Rectal Cancer Patients Treated with Postoperative Concurrent Radiochemotherapy
por: Kim, Haeyoung, et al.
Publicado: (2014)

Radiochemotherapy
Publicado: (1998)

Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer
por: Rengo, Marco, et al.
Publicado: (2017)

The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma
por: Kobus, Marta, et al.
Publicado: (2022)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice
por: Tseng, Hsiu-Ting, et al.
Publicado: (2015)

Nuclear Receptor Small Heterodimer Partner in Apoptosis Signaling and Liver Cancer
por: Zhang, Yuxia, et al.
Publicado: (2011)

Effects of neoadjuvant radiochemotherapy for anorectal function in locally advanced rectal cancer patients: a study protocol for a prospective, observational, controlled, multicentre study
por: Shi, Jie, et al.
Publicado: (2023)

Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis
por: Kim, Dong-Hyun, et al.
Publicado: (2016)

APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis
por: Hong, Se-Hoon, et al.
Publicado: (2016)

Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation
por: Yang, SeungCheon, et al.
Publicado: (2021)

Prognostic Significance of Tumor Regression in Locally Advanced Rectal Cancer after Preoperative Radiochemotherapy
por: Omejc, Mirko, et al.
Publicado: (2017)

Deletion of hepatic small heterodimer partner ameliorates development of nonalcoholic steatohepatitis in mice
por: Lee, Yoon-Kwang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_brjppehd3i2qhsioi4sqnma8r4